Company intelligence / Profile preview
PYC Therapeutics
Nedlands, Western Australia, Australiapyctx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
PYC Therapeutics is currently in clinical-stage development with programs focused on diseases of the eye, central nervous system, and kidney. Their lead program VP-001 is in Phase 1 clinical trials for the treatment of retinitis pigmentosa type 11.
- Therapeutic areas
- OphthalmologyNeurologyNephrology
- Modalities
- RNA therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on PYC Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PYC Therapeutics.